AMD updated - page 186

186
References:
1.
Lewis WH. Endothelium in tissue cultures. Am J Anat 1922;
30:39-60.
2.
Ide A. G. Baker N H. Warren S L. Vascularization of the Brown
Pearce rabbit epithelioma transplant as seen in the transparent ear
chamber. Am J Roentgenol 1939; 42; 891–899.
3.
Michaelson IC. The mode of development of the vascular system
of the retina with some observations on its significance for certain
retinal disorders. Trans Ophthalmol Soc UK 1948; 68: 137–180.
4.
Folkman J. Tumor angiogenesis: therapeutic implications. New
England Journal of Medicine 1971; 285: 1182-1186.
5.
Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vas-
cular permeability factor that promotes accumulation of ascites
fluid. Science 1983; 219: 983-5.
6.
Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel
heparin-binding growth factor specific for vascular endothelial
cells. Biochem Biophys Res Commun 1989; 161: 851-8.
7.
Connolly DT, Heuvelman D, Nelson R, et al. Tumor vascular
permeability factor stimulates endothelial cell growth and angio-
genesis. J Clin Invest 1989; 84: 1470-8.
8.
Plouet J, Schilling J, Gospodarowicz D. Isolation and characteri-
zation of a newly identified endothelial cell mitogen produced by
AtT-20 cells. EMBO J 1989; 8: 3801-6.
9.
Plate KH,Warnke PC. Vascular endothelial growth factor. J Neu-
rooncol 1997; 35 (3): 365-72.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its
receptors. Nat Med 2003; 9 (6): 669-76.
11. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW.
The vascular endothelial growth factor family: identification of a
fourth molecular species and characterization of alternative splic-
ing of RNA. Mol. Endocrinol 1991; 5: 1806–1814.
12. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF re-
ceptor signalling - in control of vascular function. Nat Rev Mol
Cell Biol 2006; 7 (5): 359-71.
13. Sheikpranbabu S, Kalishwaralal K, Venkataraman D, Eom SH,
Park J, Gurunathan S. Silver nanoparticles inhibit VEGF-and IL-
1beta-induced vascular permeability via Src dependent pathway
in porcine retinal endothelial cells. J Nanobiotechnology 2009;
7: 8.
14. Allen WR, Gower S, Wilsher S. Immunohistochemical localiza-
tion of vascular endothelial growth factor (VEGF) and its two re-
ceptors (Flt-I and KDR) in the endometrium and placenta of the
mare during the oestrous cycle and pregnancy. Reprod Domest
Anim 2007; 42 (5): 516-26.
15. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO.
Vascular endothelial growth factors and angiogenesis in eye dis-
ease. Prog Retin Eye Res 2003; 22 (1): 1-29.
16. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N,
Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT.
Vascular endothelial growth factor-A is a survival factor for reti-
nal neurons and a critical neuroprotectant during the adaptive
response to ischemic injury. Am J Pathol 2007; 171 (1): 53-67.
17. Ablonczy Z, Crosson CE. VEGF modulation of retinal pigment
epithelium resistance. Exp Eye Res 2007; 85 (6): 762-71. Epub
2007 Aug 24.
18. Takahashi H, Shibuya M. The vascular endothelial growth factor
(VEGF)/VEGF receptor system and its role under physiological
and pathological conditions. Clin Sci (Lond) 2005; 109 (3): 227-
41.
19. Slomiany MG, Rosenzweig SA. Autocrine effects of IGF-I-in-
duced VEGF and IGFBP-3 secretion in retinal pigment epithe-
lial cell line ARPE-19. Am J Physiol Cell Physiol 2004; 287 (3):
C746-53. Epub 2004 May 12.
20. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association
of vitreous inflammatory factors with diabetic macular edema.
Ophthalmology 2009; 116 (1): 73-9.
21. Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitre-
ous and aqueous concentrations of proangiogenic, antiangiogen-
ic factors and other cytokines in diabetic retinopathy patients
with macular edema: Implications for structural differences in
macular profiles. Exp Eye Res 2006; 82 (5): 798-806. Epub 2005
Dec 1.
22. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST,
Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular
endothelial growth factor in ocular fluid of patients with diabetic
retinopathy and other retinal disorders. N Engl J Med 1994; 331
(22): 1480-7.
23. Adamis, AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo
TK, and Yeo KT. Increased vascular endothelial growth factor
levels in the vitreous of eyes with proliferative diabetic retinopa-
thy. Am J Ophthalmol 1994; 118: 445-450.
24. Tsai DC, Charng MJ, Lee FL, Hsu WM, Chen SJ. Different
plasma levels of vascular endothelial growth factor and nitric ox-
ide between patients with choroidal and retinal neovascularisa-
tion. Ophthalmologica 2006; 220 (4): 246-51.
25. Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K,
Matsumura M. Expression of pigment epithelium derived factor
and vascular endothelial growth factor in choroidal neovascular
membranes and polypoidal choroidal vasculopathy. Br J Oph-
thalmol 2004; 88 (6): 809-15.
26. Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Lüke M,
Bartz-Schmidt KU, Grisanti S. Expression of VEGF and PEDF
in choroidal neovascular membranes following verteporfin pho-
todynamic therapy. Am J Ophthalmol 2006; 142 (1): 95-104.
27. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR.
Transdifferentiated retinal pigment epithelial cells are immunore-
active for vascular endothelial growth factor in surgically excised
age-related macular degeneration-related choroidal neovascular
membranes. Invest Ophthalmol Vis Sci 1996; 37 (5): 855-68.
28. Ogata N, Matsushima M, Takada Y, et al. Expression of basic
fibroblast growth factor mRNA in developing choroidal neovas-
cularization. Curr Eye Res 1996;15:1008–18.
29. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrov-
1...,176,177,178,179,180,181,182,183,184,185 187,188,189,190,191,192,193,194,195,196,...258
Powered by FlippingBook